Health
STAT+: Pharmalittle: We’re reading about a Merck AI deal, China and the pharma supply chain, and more
Publication: STAT
Author: Ed Silverman
Source published: 19/11/2026, 13:36:33 UTC
Briefing created: 19/11/2026, 14:14:11 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 19/11/2026, 13:51:24 UTC.
Briefings
A research collaboration between Merck and Isomorphic Labs was announced to develop small molecule candidates for an undisclosed oncology target. This follows the FDA approval of a Sanofi drug, Infilbray, for type 3 Gaucher disease in children aged 12 years and older weighing at least 15 kilograms. The partnership integrates Isomorphic's AI drug design engine with Merck's wet lab data for preclinical and clinical development.
Key points
- Merck and Isomorphic Labs entered a research collaboration to discover small molecule candidates for an undisclosed oncology target using Isomorphic's AI drug design engine.
- The FDA approved a Sanofi drug, Infilbray, for type 3 Gaucher disease in children aged 12 years and older weighing at least 15 kilograms.
Context
The article reports on a new partnership between a pharma giant and an AI-driven drug design firm, highlighting recent regulatory approvals for rare genetic conditions. It provides specific details on the approved drug's indication and patient criteria.
Limitations
The evidence is limited to the article's report of the Merck-Isomorphic collaboration and the FDA approval of Infilbray. Specific details about the undisclosed oncology target, the full scope of the collaboration, and the specific outcomes of the AI model are not provided in the source.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 19/11/2026, 14:14:11 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeigb66cwbgek75uddvtw367sedmlbhiizzyeqeh3j5hkdtsnidettm